Asiaticoside attenuates lipopolysaccharide-induced acute lung injury via down-regulation of NF-kappa B signaling pathway

作者:Qiu, Jiaming; Yu, Lijun; Zhang, Xingxing; Wu, Qianchao; Wang, Di; Wang, Xiuzhi; Xia, Cheng*; Feng, Haihua
来源:International Immunopharmacology, 2015, 26(1): 181-187.
DOI:10.1016/j.intimp.2015.03.022

摘要

Asiaticoside (AS), a triterpene glycoside isolated from Centella asiatica, has been shown to possess potent anti-inflammatory activity. However, the detailed molecular mechanisms of AS on lipopolysaccharide (LPS)-induced acute lung injury (ALI) model in mice are scanty. The purpose of this study was to evaluate the effect of AS on LPS-induced mouse ALL via down-regulation of NF-kappa B signaling pathway. We investigated the efficacy of AS on cytokine levels induced by LPS in bronchoalveolar lavage fluid (BALF) and RAW 264.7 cells. The production of cytokine (TNF-alpha and IL-6) was measured by enzyme-linked immunosorbent assay (ELISA). The lung wet-to-dry weight ratios were measured in LPS-challenged mice, and lung histopathologic changes observed via paraffin section were assessed. To further study the mechanism of AS protective effects on ALI, the activation of NF-kappa B p65 subunit and the degradation of I kappa B alpha were tested by western blot assay. We found that AS treatment at 15,30 or 45 mg/kg dose-dependently attenuated LPS-induced pulmonary inflammation by reducing inflammatory infiltration, histopathological changes, descended cytokine production, and pulmonary edema initiated by LPS. Furthermore, our results suggested that AS suppressed inflammatory responses in LPS-induced ALI through inhibition of the phosphorylation of NF-kappa B p65 subunit and the degradation of its inhibitor I kappa B alpha, and might be a new preventive agent of ALI in the clinical setting.